Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
News for 60 Degrees Pharmaceuticals, Inc. (warrants: SXTPW) centers on its activities as a pharmaceutical company focused on developing and commercializing medicines for vector-borne diseases. Company announcements repeatedly highlight work in malaria prevention through its FDA-approved product ARAKODA (tafenoquine), as well as clinical research programs in babesiosis, an emerging tick-borne illness for which no FDA-approved treatment currently exists.
Investors and observers following SXTPW-related news will see updates on clinical trial milestones, including the B-FREE Chronic Babesiosis Study (NCT06656351) and other tafenoquine studies in hospitalized and relapsing babesiosis patients. Releases describe study designs, enrollment progress, and early findings such as Babesia detection rates in chronic fatigue cohorts or parasite status in individual patients completing treatment regimens.
Company news also covers commercial and marketing developments for ARAKODA, such as expansion of inside sales teams, partnerships with platforms like GoodRx to broaden offer visibility, and digital marketing campaigns aimed at prescribers. Financial updates, including quarterly results and commentary on product demand trends, appear alongside these operational highlights.
Regulatory and capital markets items form another important news category. Examples include announcements of reverse stock splits intended to support continued Nasdaq listing, at-the-market sales agreements for common stock, and participation in investor conferences where management presents the company’s vector-borne disease strategy.
For readers tracking SXTPW, the news stream offers a view into how 60 Degrees Pharmaceuticals advances its malaria franchise, builds a babesiosis clinical program, manages its Nasdaq-listed securities, and collaborates with academic and research institutions in the U.S. and Australia. Bookmark this page to follow ongoing disclosures about trials, regulatory interactions, financing transactions, and other material events tied to the company’s warrants and underlying common stock.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced the potential market size for ARAKODA® (tafenoquine) in treating human babesiosis, projecting maximum annual sales of $245 million and a cumulative market value of $1.1 billion through patent expiration in 2035.
The market assessment is based on comprehensive research including a 6,000-patient nationwide survey and feedback from 300 healthcare professionals. The company estimates a total addressable market of 380,000 patients annually.
Currently, three clinical trials are underway or planned to evaluate tafenoquine's safety and efficacy. The company expects to submit a New Drug Application (NDA) to the FDA in 2026, pending positive trial results.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced plans to submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. The submission will be supported by three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, including one company-sponsored study at North Carolina State University.
The studies demonstrated that tafenoquine was well-tolerated and effective in treating both experimental and naturally acquired Babesia infections in dogs. This development is significant as there are currently no FDA-approved oral treatments for canine babesiosis, an emerging tick-borne illness that affects hundreds to thousands of dogs annually in the United States.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has reported its Q1 2025 financial results, showing mixed performance. The company's net product revenues increased 55% year-over-year to $163.6 thousand, primarily driven by domestic sales of ARAKODA®. Gross profit saw significant growth of 124%, reaching $90.3 thousand compared to $40.2 thousand in Q1 2024.
However, operating expenses rose to $2.09 million from $1.41 million in the previous year, with $535.4 thousand attributed to increased sales, investor-related services, and stock-based compensation. The company reported a net loss of $2.01 million ($1.56 per share) in Q1 2025, compared to a net income of $308.7 thousand ($1.83 per share) in Q1 2024, largely due to a $1.74 million change in fair value of derivative liabilities.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reveals groundbreaking survey results suggesting babesiosis disease burden in the US is significantly higher than CDC estimates. The survey, conducted among 6,000 US adults, found that 1.26% of respondents (equivalent to ~3 million people) reported receiving a babesiosis diagnosis in their lifetime, compared to CDC's 1,834 reported cases in 2020.
The study indicates that approximately 17% of babesiosis patients experienced illness lasting six months or more, suggesting around 570,000 US adults have faced chronic disease. Additionally, 3.7% of respondents (~9.9 million Americans) reported experiencing chronic fatigue lasting longer than six months, with 56% of these individuals having received a formal Chronic Fatigue Syndrome diagnosis.
This significant disparity between survey findings and CDC statistics suggests babesiosis may be substantially underdiagnosed or underreported, potentially indicating a larger market for effective treatments.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Geoff Dow will participate in the Healing Lyme Summit from April 15-21, 2025, to discuss babesiosis, a tick-borne disease commonly occurring alongside Lyme disease. Dr. Dow will address the increasing prevalence of babesiosis in the United States, clinical challenges, and the need for better diagnostic and treatment options.
The company is currently conducting two clinical trials (NCT06207370 and NCT06478641) evaluating tafenoquine for treating severe babesiosis and persistent disease in immunosuppressed patients. The summit is a free virtual event featuring scientific discussions and educational content on tick-borne illnesses.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has signed a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to advance the development and commercialization of tafenoquine for babesiosis treatment and prevention.
The agreement follows collaborative research between the organizations studying tafenoquine's activity against babesiosis, a tick-borne disease that infects red blood cells. Currently, tafenoquine is not FDA-approved for babesiosis treatment and prevention.
If approved, tafenoquine could address a significant unmet medical need, particularly for patients who progress beyond initial mild symptoms. The drug could potentially become the first prophylaxis available for babesiosis. According to Dr. Peter James Krause from Yale, relapsing babesiosis in immunocompromised patients has an estimated mortality rate of 20 percent and is challenging to treat.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported significant financial growth for FY 2024. Net product revenues increased 140% to $607.6 thousand, driven by domestic sales of ARAKODA®. The company achieved a gross profit of $222.8 thousand in 2024, compared to a $221 thousand loss in 2023.
Operating expenses rose to $10.0 million in 2024 from $4.9 million in 2023, primarily due to non-recurring R&D charges and babesiosis clinical trial costs. Net loss widened to $8.43 million ($18.55 per share) from $3.925 million ($59.18 per share) in 2023.
Key developments include:
- FDA approval to import Kodatef® (Australian equivalent of Arakoda) due to increased U.S. demand
- Ongoing babesiosis clinical trials with interim analysis expected in Q1 2026
- Additional Arakoda supply lots scheduled for release in early Q2 2025
- Expansion of clinical studies for babesiosis treatment in various patient groups
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a 1-for-5 reverse stock split of its common stock, effective February 24, 2025. The primary purpose is to comply with Nasdaq's $1.00 minimum bid price requirement to maintain listing. The stock will continue trading under 'SXTP' with a new CUSIP number 83006G401.
The reverse split will automatically convert every five current shares into one new share. Proportional adjustments will be made to outstanding equity awards, warrants, convertible notes, and shares under stock incentive plans. The split won't alter the par value, authorized share count, or stockholders' percentage ownership. No fractional shares will be issued; all will be rounded up to the next whole share.
Stockholders don't need to take action, as positions will be automatically adjusted. The company notes there's no guarantee it will meet the minimum bid requirement.